Research Radartracking 1,138 published studies · 277 human · 6 safety signals · 42 clinical trials · 44 cancer pages · updated Jul 2026Open the Research Map →

Lenvatinib

← All agents

Human-reviewed · How we review →

AI extractedhuman reviewedsources checkedretractions suppressed

Evidence at a glanceInsufficient evidenceMixed results⚠ Studies disagree
3 published studies tagged to this agent0 human studies approved & graded (trial, observational, or meta-analysis)
Why this grade?

Insufficient evidence — No primary experimental studies yet.

  • 0 human · 0 animal · 0 lab · 3 review/other
  • Most authoritative study: Endometrial carcinosarcoma
  • Studies disagree on the reported direction (conflict flagged).
  • No human studies yet
  • Findings conflict across studies
  • Effect sizes reported in only 2 of 3 studies

Computed deterministically from the studies’ types and reported outcomes — not written by AI, and not a claim that anything works.

Auto-discovered · not yet curatedlenvatinib
Educational only, not medical advice. OncoForge makes no claim that Lenvatinib treats, prevents, or cures any condition, beyond what the linked studies show. Evidence levels vary; effects may not translate to people, and some compounds can cause harm. Always coordinate with your oncology team.

Simple Summary

Auto-discovered from 1 recent study; not yet curated.

Research

Where the evidence is

What has been studied, and how strong it is, by topic. A dashed cell means no studies were found for that combination — a gap, not evidence of no effect. Open a row to see its studies.

CancerHuman evidenceMechanismSafetyTrial
Uterine Serous Carcinoma—2——
Endometrial Cancer—1——
Endometrial Carcinosarcoma—1——

Study mix

3 published studies by what they were done in. Lab and animal findings often do not carry over to people.

3 Review/other
Reported directionReported positive2Mixed results1

What supports this page

The kinds of sources behind this page, strongest at the top. Faint rungs show what is not here yet.

Guideline
0
Meta-analysis
0
Systematic review
0
Randomized trial
0
Clinical trial
0
Observational
0
Case report
0
Review
3
Preclinical
0
Other
0
3 studies3 review/other

Tracking 3 published studies of Lenvatinib: 3 reviews/other.

Reported direction across studies: 2 positive, 1 mixed.

Findings conflict — both supportive and negative/mixed results exist (see below). Human evidence is absent so far.

These counts summarize what the studies reported; they are not a measure of whether Lenvatinib works.

Cancers named in these studies

uterine serous carcinoma (2)endometrial carcinosarcoma (1)endometrial cancer (1)

Conflicting evidence

All studies

ReviewMechanismMixed resultsLimited evidenceTier 4 · clinical

Endometrial carcinosarcoma

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society · Feb 2023

CarboplatinLenvatinibPaclitaxelPembrolizumabendometrial carcinosarcoma

This review summarizes current knowledge on endometrial carcinosarcoma, an aggressive high-grade endometrial carcinoma with sarcomatous trans-differentiation that is often diagnosed at an advanced stage. It describes common molecular features (frequent p53 abnormalities; variable POLE/MSI-H) and current management: multimodal therapy with optimal surgery plus chemotherapy and radiotherapy, carboplatin/paclitaxel as first-line systemic therapy for recurrent/metastatic disease, and regulatory approvals for pembrolizumab plus lenvatinib in endometrial cancer generally. The authors note that carcinosarcoma patients were excluded from many immunotherapy trials and that emerging molecular insights may enable more personalized treatments in the future.

Reported effects: proportion_in_endometrioid_components 25% · proportion_in_non-endometrioid_components 3%

Studied with: carboplatin/paclitaxel doublet, pembrolizumab + lenvatinib, concomitant or sequential chemotherapy and radiotherapy, surgery plus chemotherapy and radiotherapy (multimodal).

Key findings
  • Endometrial carcinosarcoma is a rare, aggressive high-grade endometrial carcinoma with secondary sarcomatous trans-differentiation.
  • Clinical presentation and diagnostic work-up are similar to endometrioid endometrial cancer, but carcinosarcoma is more frequently diagnosed at an advanced stage.
  • Endometrial carcinosarcoma encompasses different histological subtypes depending on the carcinomatous and sarcomatous elements.
  • The majority of endometrial carcinosarcomas are characterized by p53 abnormalities.
  • The proportion of POLE and microsatellite instability-high (MSI-H) is related to the epithelial component, being approximately 25% and 3% in endometrioid and non-endometrioid components.
  • Non-metastatic disease management is multimodal with optimal surgery followed by concomitant or sequential chemotherapy and radiotherapy, even for early stages.
  • Palliative chemotherapy is recommended for metastatic or recurrent disease, with carboplatin/paclitaxel doublet as the first-line regimen.
  • Patients with endometrial carcinosarcoma were excluded from most studies evaluating single-agent immunotherapy or combinations, although pembrolizumab and lenvatinib have FDA and EMA approvals in endometrial cancer after progression on chemotherapy (and single-agent immunotherapy in MSI-H cancers).
  • Emerging molecular knowledge is opening promising therapeutic options for more personalized treatment.
Limitations: This article is a narrative review rather than primary clinical trial data.; Endometrial carcinosarcoma is a rare and heterogeneous disease, limiting generalizable high-quality evidence.; Patients with carcinosarcoma were excluded from most immunotherapy studies, resulting in limited direct trial evidence for these agents in this histotype.; The abstract does not present new quantitative clinical trial outcomes specific to carcinosarcoma..

AI summary of the abstract, human-reviewed · Jun 2026. Describes what this study reported, not medical advice. View on PubMed

ReviewReported positiveLimited evidenceTier 4 · clinical

Targeted Therapies in the Treatment of Uterine Serous Carcinoma

Current treatment options in oncology · Dec 2022

PembrolizumabLenvatinibuterine serous carcinoma

This narrative review summarizes targeted therapy options for uterine serous carcinoma. It states that adding trastuzumab to conventional chemotherapy is indicated for HER2-positive advanced or recurrent disease, and that pembrolizumab plus lenvatinib showed about a 50% response rate in women with recurrent disease. The review highlights several emerging targeted approaches (ADCs, PARP, WEE1, AKT inhibitors and combinations of immunotherapy and TKIs) and recommends enrollment in clinical trials.

Reported effect: response_rate (pembrolizumab + lenvatinib) 50%

Studied with: chemotherapy (trastuzumab + chemotherapy), pembrolizumab + lenvatinib, combinations of immunotherapies and tyrosine kinase inhibitors.

Key findings
  • For HER2-positive uterine serous carcinoma, the addition of trastuzumab to conventional chemotherapy is indicated in advanced stage and/or recurrent disease.
  • Treatment with pembrolizumab and lenvatinib suggests a 50% response rate in women with recurrent disease.
  • Emerging targeted options include antibody-drug conjugates targeting HER2, folic acid receptor alpha, or Trop-2; combinations of immunotherapies and tyrosine kinase inhibitors; PARP inhibitors; WEE1 inhibitors; and AKT inhibitors.
  • Several trials evaluating these targeted agents are ongoing and results are pending.
  • The authors recommend enrollment of patients in clinical trials to provide more personalized care.
Limitations: Narrative review rather than primary clinical trial data; no new patient-level data presented in this abstract.; Many discussed agents are investigational and the abstract notes that several trials are ongoing (mature results not presented).; Abstract provides limited quantitative data and no methodological details (search strategy, inclusion criteria) are described.; Heterogeneity and quality of the underlying studies are not detailed in the abstract..

AI summary of the abstract, human-reviewed · Jun 2026. Describes what this study reported, not medical advice. View on PubMed

ReviewReported positiveModerate evidenceTier 4 · clinical

Uterine serous carcinoma: key advances and novel treatment approaches

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society · Aug 2021 · Review

PembrolizumabLenvatinibuterine serous carcinomaendometrial cancer

This review summarizes molecular drivers and recent therapeutic advances for uterine serous carcinoma. It highlights HER2 amplification as an actionable target and notes that adding trastuzumab to standard chemotherapy is associated with improved survival in advanced/recurrent HER2-positive disease. The authors also report a phase II study suggesting a 50% response rate for pembrolizumab plus lenvatinib in recurrent disease.

Studied with: trastuzumab + conventional chemotherapy, pembrolizumab + lenvatinib.

Key findings
  • Incidence and mortality from endometrial cancer are increasing worldwide; uterine serous carcinoma accounts for a small fraction of cases but nearly 40% of endometrial cancer deaths.
  • Black women are disproportionately affected, with higher rates of advanced disease at diagnosis.
  • Frequent molecular alterations include TP53, PIK3CA, ERBB2 (HER2) amplification, CCNE1 amplification, FBXW7 mutation/deletion, PPP2R1A mutation, and somatic mutations in homologous recombination genes.
  • Clinical risk factors include advancing age, history of breast cancer, tamoxifen use, and hereditary breast-ovarian cancer syndrome.
  • Surgery remains the cornerstone of treatment.
  • HER2 overexpression/amplification is an actionable target; adding trastuzumab to conventional chemotherapy is associated with improved survival in women with advanced and recurrent HER2-positive disease.
  • The combination of pembrolizumab and lenvatinib is a promising strategy, with a phase II study suggesting a 50% response rate in women with recurrent disease.
  • Multiple additional targeted-agent trials are ongoing.
Limitations: This is a review article summarizing prior studies and does not present new primary patient-level data.; Some clinical evidence cited (e.g., a phase II study) is early-phase and may have limited sample size or non-randomized design.; The abstract does not provide sample sizes, statistical details, or full trial designs for the cited studies.; Uterine serous carcinoma is an uncommon subtype, which can limit the size and generalizability of studies..

AI summary of the abstract, human-reviewed · Jun 2026. Describes what this study reported, not medical advice. View on PubMed

What changed recently

The latest additions to Lenvatinib's evidence base, and anything that's been retracted.

Recently added

Cancers where Lenvatinib reported positive results

Where at least one study reported a positive result, shown with the full picture, not just the wins. Positive results are more likely to be published, and most of these are early lab or animal studies that may not translate to people. This reports what studies found, not what works.

Preclinical only: lab / animal (2)
Limitations: Narrative review rather than primary clinical trial data; no new patient-level data presented in this abstract.; Many discussed agents are investigational and the abstract notes that several trials are ongoing (mature results not presented).; Abstract provides limited quantitative data and no methodological details (search strategy, inclusion criteria) are described.; Heterogeneity and quality of the underlying studies are not detailed in the abstract.; This is a review article summarizing prior studies and does not present new primary patient-level data.; Some clinical evidence cited (e.g., a phase II study) is early-phase and may have limited sample size or non-randomized design..
Cited positive studies (2)
Limitations: This is a review article summarizing prior studies and does not present new primary patient-level data.; Some clinical evidence cited (e.g., a phase II study) is early-phase and may have limited sample size or non-randomized design.; The abstract does not provide sample sizes, statistical details, or full trial designs for the cited studies.; Uterine serous carcinoma is an uncommon subtype, which can limit the size and generalizability of studies..
Cited positive studies (1)

Evidence at a glance: Lenvatinib by cancer

A deterministic grade of what published studies report for each: strength of evidence, the reported direction, and the largest credible effect, strongest-evidence first. This summarizes findings; it is not a claim that anything works.

Uterine serous carcinomaInsufficient evidenceReported positive

No primary experimental studies yet.

Largest credible effect: response_rate (pembrolizumab + lenvatinib) 50% PMID 36447064

Most authoritative study: Targeted Therapies in the Treatment of Uterine Serous Carcinoma

No human studies yet · Effect sizes reported in only 1 of 2 studies.
Endometrial cancerInsufficient evidenceReported positive

No primary experimental studies yet.

Most authoritative study: Uterine serous carcinoma: key advances and novel treatment approaches

No human studies yet · No numeric effect sizes reported · Based on a single study.
Endometrial carcinosarcomaInsufficient evidenceMixed results

No primary experimental studies yet.

Largest credible effect: proportion_in_endometrioid_components 25% PMID 36585027 · effect sizes 3–25 across 2 studies

Most authoritative study: Endometrial carcinosarcoma

No human studies yet · Based on a single study.

Clinical trials studying Lenvatinib

7 ongoing · 2 completed · tracked from ClinicalTrials.gov. Recruiting is not the same as proven, and completed is not the same as positive — read the results. Not a recommendation.

Completed
1 stopped (terminated / withdrawn / suspended)

Search all trials on ClinicalTrials.gov →

Inclusion here is not an endorsement. OncoForge makes no claim beyond what the linked studies show. Discuss anything on this page with your oncology team before acting on it.

← All agents · Research Radar